Comparison of ⁶⁴Cu-DOTA-PSMA-3Q and ⁶⁴Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging.

ABSTRACT:

Objective

This study aims to investigate the efficacy and safety of prostate-specific membrane antigen (PSMA) radiolabeled with copper-64 (⁶⁴Cu) using the bifunctional chelating agents (BFCAs) NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). As widely utilized BFCAs in the development of radiopharmaceuticals, NOTA and DOTA play a critical role in ensuring stable chelation with ⁶⁴Cu. This study evaluates the stability, bioavailability, and therapeutic potential of these radiolabeled compounds in preclinical models and initial clinical trials.

Methods

⁶⁴Cu-DOTA-PSMA-3Q and ⁶⁴Cu-NOTA-PSMA-3Q were synthesized by manual labeling. The radiochemical purity, stability,

SUBMITTER: Liu H 

PROVIDER: S-EPMC12162759 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature